Abstract

Introduction: It is widely known that drug-eluting stents (DES) induce coronary vasomotion abnormalities. We have previously demonstrated that chronic treatment with long-acting nifedipine, which exerts cardiovascular protective effects through inhibition of vascular inflammation, suppresses DES-induced abnormal coronary vasoconstriction in pigs. In order to test whether this is also the case in humans, we performed a prospective, randomized, multicenter trial, termed as the NOVEL Study. Methods and Results: We enrolled 146 patients with stable angina pectoris who underwent elective implantation of everolimus-eluting stents (EES) in the left coronary arteries. They were randomly assigned to receive either conventional treatments alone (aspirin, clopidogrel, renin-angiotensin system inhibitor and statin) or additionally long-acting nifedipine (10-60 mg/day) (n=73 each). After 8-10 months, 53 patients in the control and 57 in the nifedipine group were finally examined for coronary reactivity to intracoronary acetylcholine (ACh) by quantitative coronary angiography after 48-hour withdrawal of nifedipine. Baseline patient characteristics and procedural profiles were comparable between the two groups. Coronary vasoconstricting responses to ACh were significantly enhanced at the distal segment adjacent to EES as compared with non-stented vessel (P<0.001) and were significantly inhibited in the nifedipine group (P<0.01) (Figure). Furthermore, the inflammatory profiles, including serum levels of high-sensitivity CRP and adiponectin, were improved only in the nifedipine group (P<0.05) (Figure). Conclusions: These results indicate that DES-induced coronary vasomotion abnormalities still remain an important clinical issue even with the second-generation of DES, for which long-acting nifedipine exerts beneficial effects associated with its anti-inflammatory effects.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.